Five successive waves of SARS-CoV-2 infection in the Central African Republic: a prospective observational study from 2020-2022.
COVID-19
Central African Republic
SARS-CoV-2
Journal
The Pan African medical journal
ISSN: 1937-8688
Titre abrégé: Pan Afr Med J
Pays: Uganda
ID NLM: 101517926
Informations de publication
Date de publication:
2023
2023
Historique:
received:
03
03
2023
accepted:
30
11
2023
medline:
12
3
2024
pubmed:
11
3
2024
entrez:
11
3
2024
Statut:
epublish
Résumé
the National Laboratory of Clinical Biology and Public Health (NLBPH) in Bangui in the Central African Republic (CAR) carries out the vast majority of molecular screening tests for SARS-CoV-2 infection nationwide. This study aimed to show the contribution of molecular diagnosis and genomic surveillance in monitoring the evolution of longitudinal variations of the SARS-CoV-2 infection epidemic in CAR between 2020 and the end of 2022. this is an observational study on the variations in the prevalence of detection of SARS-CoV-2 by RT-PCR at the NLCBPH from nasopharyngeal samples taken prospectively over a period of 3 years since the beginning of the COVID-19 epidemic. A subgroup of SARS-CoV-2 positive samples was selected for molecular sequencing performed by Illumina® and MinIon® at the National Institute for Biomedical Research in Kinshasa, Democratic Republic of the Congo. from March 2020 to December 31 this prospective study over a period of 3 years, marked by 5 successive waves, made it possible to report that age, sex and the presence of clinical symptoms are associated with RT-PCR positivity. Among the different variants identified during successive waves, the Omicron variant predominated during the last two waves.
Identifiants
pubmed: 38465007
doi: 10.11604/pamj.2023.46.120.39511
pii: PAMJ-46-120
pmc: PMC10924610
doi:
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
120Informations de copyright
Copyright: Clotaire Donatien Rafaï et al.
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Rev Francoph Lab. 2020 Nov;2020(526):48-56
pubmed: 33163104
Rev Francoph Lab. 2021 Jan;2021(528):36-42
pubmed: 33437317
Int J Infect Dis. 2022 Sep;122:136-143
pubmed: 35598737
Bull Acad Natl Med. 2023 Feb;207(2):150-164
pubmed: 36628105
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
Cell. 2022 Aug 4;185(16):2952-2960.e10
pubmed: 35809570
Bull Acad Natl Med. 2021 May;205(5):435-438
pubmed: 33658724
PLOS Glob Public Health. 2023 Nov 1;3(11):e0001497
pubmed: 37910467
Nat Commun. 2021 Oct 1;12(1):5769
pubmed: 34599175